3 November 2025 ORYZON announces First‑Patient‑In (FPI) in RESTORE Phase Ib trial of iadademstat in sickle cell disease
28 October 2025 ORYZON strengthens regulatory strategy with the appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs
17 October 2025 ORYZON receives feedback from the FDA in response to the submitted Phase III protocol in Borderline Personality Disorder
1 October 2025 ORYZON strengthens patent portfolio for iadademstat with European grant decision covering combinations with PD1/PD-L1 inhibitors
16 September 2025 ORYZON strengthens patent portfolio for iadademstat and vafidemstat with new Decisions to Grant